LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Home・Aktien・Essa Pharma Inc

Essa Pharma Inc

Geschlossen

1.71 1.79

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.68

Max

1.71

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.2M -6.4M
EPS	-0.195
Angestellte	35
EBITDA	-2.2M -8.5M

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-1.3M 75M
Vorheriger Eröffnungskurs	-0.08
Vorheriger Schlusskurs	1.71

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

1.7 / 1.72 Unterstützung & Widerstand

Essa Pharma Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Mai 2025, 22:52 UTC

Ergebnisse

Wichtige Markttreiber

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15. Mai 2025, 20:37 UTC

Top News

Ergebnisse

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16. Mai 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15. Mai 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15. Mai 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Mai 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15. Mai 2025, 23:14 UTC

Top News

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15. Mai 2025, 22:46 UTC

Top News

Akquisitionen, Fusionen, Übernahmen

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. Mai 2025, 21:58 UTC

Ergebnisse

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15. Mai 2025, 21:24 UTC

Ergebnisse

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15. Mai 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15. Mai 2025, 20:54 UTC

Market Talk

Ergebnisse

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15. Mai 2025, 20:54 UTC

Ergebnisse

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15. Mai 2025, 20:51 UTC

Ergebnisse

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15. Mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15. Mai 2025, 20:50 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15. Mai 2025, 20:50 UTC

Ergebnisse

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15. Mai 2025, 20:26 UTC

Top News

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15. Mai 2025, 20:25 UTC

Ergebnisse

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Peer-Vergleich

Kursveränderung

Essa Pharma Inc Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Essa Pharma Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.7 / 1.72Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Essa Pharma Inc

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.